PL447202A1 - Związek będący inhibitorem oddziaływania PD-L1/PD-1, kompozycja farmaceutyczna zawierająca inhibitor, oraz zastosowanie inhibitora - Google Patents

Związek będący inhibitorem oddziaływania PD-L1/PD-1, kompozycja farmaceutyczna zawierająca inhibitor, oraz zastosowanie inhibitora

Info

Publication number
PL447202A1
PL447202A1 PL447202A PL44720223A PL447202A1 PL 447202 A1 PL447202 A1 PL 447202A1 PL 447202 A PL447202 A PL 447202A PL 44720223 A PL44720223 A PL 44720223A PL 447202 A1 PL447202 A1 PL 447202A1
Authority
PL
Poland
Prior art keywords
inhibitor
compound
interaction
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Application number
PL447202A
Other languages
English (en)
Inventor
Radosław KITEL
Jan KONOPKA
Miłosz MOCARSKI
Łukasz Skalniak
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL447202A priority Critical patent/PL447202A1/pl
Priority to PCT/PL2024/050104 priority patent/WO2025136134A1/en
Publication of PL447202A1 publication Critical patent/PL447202A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Pierwszym przedmiotem zgłoszenia jest związek o wzorze ogólnym I i/lub jego farmaceutycznie akceptowalne sole. Zgłoszenie obejmuje również kompozycję farmaceutyczną zawierającą związek określony wzorem ogólnym I i/ lub jego farmaceutycznie dopuszczalną sól oraz farmaceutycznie dopuszczalny nośnik. Innym przedmiotem zgłoszenia jest zastosowanie wspominanego związku jako inhibitora oddziaływania PD-L1/PD-1 oraz stosowanie go do przygotowywania leku do zapobiegania i/lub leczenia choroby zależnej od szlaku PD-1/PD-L1.
PL447202A 2023-12-21 2023-12-21 Związek będący inhibitorem oddziaływania PD-L1/PD-1, kompozycja farmaceutyczna zawierająca inhibitor, oraz zastosowanie inhibitora PL447202A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL447202A PL447202A1 (pl) 2023-12-21 2023-12-21 Związek będący inhibitorem oddziaływania PD-L1/PD-1, kompozycja farmaceutyczna zawierająca inhibitor, oraz zastosowanie inhibitora
PCT/PL2024/050104 WO2025136134A1 (en) 2023-12-21 2024-12-20 Dimethylbiphenyl covalent pd-l1/pd-1 interaction inhibitor compound, pharmaceutical composition containing said inhibitor and the use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL447202A PL447202A1 (pl) 2023-12-21 2023-12-21 Związek będący inhibitorem oddziaływania PD-L1/PD-1, kompozycja farmaceutyczna zawierająca inhibitor, oraz zastosowanie inhibitora

Publications (1)

Publication Number Publication Date
PL447202A1 true PL447202A1 (pl) 2025-06-23

Family

ID=94734042

Family Applications (1)

Application Number Title Priority Date Filing Date
PL447202A PL447202A1 (pl) 2023-12-21 2023-12-21 Związek będący inhibitorem oddziaływania PD-L1/PD-1, kompozycja farmaceutyczna zawierająca inhibitor, oraz zastosowanie inhibitora

Country Status (2)

Country Link
PL (1) PL447202A1 (pl)
WO (1) WO2025136134A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191624A1 (en) * 2018-03-29 2019-10-03 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
EP3750887A1 (en) * 2018-02-05 2020-12-16 Abbisko Therapeutics Co., Ltd. Biaryl derivative, preparation method thereof and pharmaceutical application thereof
PL439107A1 (pl) * 2021-09-30 2023-04-03 Recepton Spółka Z Ograniczoną Odpowiedzialnością Podstawione pochodne 1,1´-bifenylu w połączeniu z aminokwasami i dipeptydami do stosowania w immunoterapii nowotworów
PL441982A1 (pl) * 2022-08-09 2024-02-12 Recepton Spółka Z Ograniczoną Odpowiedzialnością Niesymetrycznie podstawione pochodne 1,1'-bifenylu do stosowania w immunoterapii nowotworów

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210040118A1 (en) * 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3750887A1 (en) * 2018-02-05 2020-12-16 Abbisko Therapeutics Co., Ltd. Biaryl derivative, preparation method thereof and pharmaceutical application thereof
WO2019191624A1 (en) * 2018-03-29 2019-10-03 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
PL439107A1 (pl) * 2021-09-30 2023-04-03 Recepton Spółka Z Ograniczoną Odpowiedzialnością Podstawione pochodne 1,1´-bifenylu w połączeniu z aminokwasami i dipeptydami do stosowania w immunoterapii nowotworów
PL441982A1 (pl) * 2022-08-09 2024-02-12 Recepton Spółka Z Ograniczoną Odpowiedzialnością Niesymetrycznie podstawione pochodne 1,1'-bifenylu do stosowania w immunoterapii nowotworów

Also Published As

Publication number Publication date
WO2025136134A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
MX2023007192A (es) Inhibidores de prmt5.
MX2025001619A (es) Inhibidor de pde4b y uso del mismo
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2022003984A (es) Compuestos heterociclicos antivirales.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
NZ793536A (en) Imidazolidinone derivatives and medical use thereof
EA200602260A1 (ru) Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам
CL2024000067A1 (es) Compuestos antivirales
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
BR112021022255A2 (pt) Composto usado como inibidor de quinase e aplicação do mesmo
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
JOP20220076A1 (ar) مثبطات عامل d المكمل عن طريق الفم
PH12022550790A1 (en) Oral complement factor d inhibitors
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
ZA202501471B (en) Preparation and use of quinazolinone derivative as kinase inhibitor
JOP20220281A1 (ar) مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
BR112022020933A2 (pt) Inibidores de replicação do vírus da imunodeficiência humana
MX2022015679A (es) Inhibidor de tyk-2.
MX2025011458A (es) Inhibidor de cyp11a1 y uso del mismo
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4